 |
 |
|
|
|
|
|
|
|
| | | |
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
1
.
COMPLAINT
|
EXTRACTED KEY WORDS
SYMLIN DRUG DIABETES FDA TREATMENT PRAMLINTIDE ACETATE DRUG CANDIDATE COMMERCIALIZATION METABOLIC DISORDERS REVIEW SECURITIES CLASS ACTION ADVISORY COMMITTEE INSULIN ADMINISTRATION STATISTICIANS HYPOGLYCEMIA ADVISORY COMMITTEE MEETING SYMLINTM DEFENDANTS PRIVATE PLACEMENT SUBMISSION NDA MEDICAL PRACTICE COMMON STOCK REGULATORY PURCHASERS ADVERSE EVENTS DEVELOPMENT PROGRAM |
1 MILBERG WEISS BERSHAD
HYNES & LERACH LLP
2 WILLIAM S. LERACH (68581)
DARREN J. ROBBINS (168593)
3 600 West Broadway, Suite 1800
San Diego, CA 92101
4 Telephone: 619/231-1058
619/231-7423 (fax)
5 Attorneys for Plaintiff
6
7
8 UNITED STATES DISTRICT COURT
9 SOUTHERN DISTRICT OF CALIFORNIA
10 HARVEY RASKIND, On Behalf of ) No.
11 Himself and All Others Similarly )
Situated, ) CLASS ACTION
12 )
Plaintiff, ) COMPLAINT FOR VIOLATION OF THE
13 ) FEDERAL SECURITIES LAWS
vs. )
14 )
AMYLIN PHARMACEUTICALS, INC. and )
15 JOSEPH C. COOK, JR., ))
16 Defendants. )) DEMAND FOR JURY TRIAL
17
18
19
20
21
22
23
24
25
26
27
SNIPPETS:
|
|
|
| | | |
|
|
